General / Multi-Specialty A
Elixhauser Comorbidity Index
Measures comorbidity burden using 31 weighted conditions. Predicts in-hospital mortality, length of stay, and resource utilisation.
Score interpretation
Low Comorbidity Burden -99–0
Elixhauser score <= 0. Low comorbidity burden.
→ Standard care pathway.
Moderate Comorbidity 1–10
Score 1-10: Moderate comorbidity. Increased risk of complications.
→ Optimise modifiable risk factors. MDT approach.
High Comorbidity Burden ≥ 11
Score >10: High comorbidity burden. Elevated mortality and complication risk.
→ High-risk pathway. Senior review. Prognosis discussion appropriate.
Interpretation bands for the Elixhauser. Apply clinical judgement and local guidance.
References
- Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
- van Walraven C, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death. Med Care. 2009;47(6):626-633.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.